CJC-1295 no DAC (5mg)
Spécifications techniques
| Pureté (HPLC) | ≥99% (HPLC) |
| Numéro CAS | 863288-34-0 |
| Forme | White lyophilized powder |
| Stockage | -20°C |
| Séquence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ |
| Poids moléculaire | 3,367.89 g/mol |
| Forme saline | Acetate |
| Solubilité | Soluble in water |
CJC-1295 no DAC (5mg)
Prix catalogue EUR · HU, SK, CZ, PL
- Eurozone (EUR)44,99 EUR
- Hongrie (HU)44,99 EUR≈ 17 996 Ft
- Slovaquie (SK)44,99 EUR
- Tchéquie (CZ)44,99 EUR≈ 1 125 Kč
- Pologne (PL)44,99 EUR≈ 191,21 zł
Même prix catalogue en EUR pour livraison vers la Hongrie, la Slovaquie, la République tchèque et la Pologne. Paiement en EUR.
Montants HUF/CZK/PLN indicatifs convertis depuis l’EUR ; la Slovaquie utilise l’EUR. Taux approximatifs. Paiement en EUR.
Growth hormone-releasing hormone (GHRH) analog. For laboratory research use only.
Strictement réservé à la recherche en laboratoire.
Non destiné à la consommation humaine, vétérinaire ou au diagnostic.
From the Peptide Explorer
A synthetic 29-amino-acid analog of GHRH with four amino acid substitutions that dramatically increase metabolic stability. Unlike the DAC (Drug Affinity Complex) version, the no-DAC form preserves pulsatile GH release patterns, which is considered more physiological.
Key Mechanisms
- ›GHRH receptor agonism
- ›Pulsatile GH release promotion
- ›Synergy with GHSR agonists (ipamorelin)
- ›Somatostatin-sensitive (preserves feedback)
- ›Enhanced half-life via amino acid substitutions
Primary Research Areas
- ›GH axis physiology
- ›Pulsatile GH release
- ›Body composition
- ›Combined secretagogue protocols
Key Research Findings
- 4 amino acid substitutions increased half-life ~4x vs native GHRH(1-29)
- Preserved pulsatile GH release pattern (unlike CJC-1295 with DAC)
- Synergistic GH amplification with ipamorelin in human subjects
Research Overview
A synthetic 29-amino-acid analog of GHRH with four amino acid substitutions that dramatically increase metabolic stability. Unlike the DAC (Drug Affinity Complex) version, the no-DAC form preserves pulsatile GH release patterns, which is considered more physiological.
Origin: Modified analog of Growth Hormone Releasing Hormone (GHRH) 1-29
Mechanism of Action
- GHRH receptor agonism
- Pulsatile GH release promotion
- Synergy with GHSR agonists (ipamorelin)
- Somatostatin-sensitive (preserves feedback)
- Enhanced half-life via amino acid substitutions
Primary Research Areas
- GH axis physiology
- Pulsatile GH release
- Body composition
- Combined secretagogue protocols
Key Published Findings
- 4 amino acid substitutions increased half-life ~4x vs native GHRH(1-29)
- Preserved pulsatile GH release pattern (unlike CJC-1295 with DAC)
- Synergistic GH amplification with ipamorelin in human subjects
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized, 2-8°C reconstituted
Important Notice
CJC-1295 no DAC (5mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Spécifications de recherche
Synthesized for strict analytical consistency. Verified via HPLC/MS.Voir les standards qualité →
Manipulation et stockage
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water